SCHEMBL3886901

SCHEMBL3886901

COc1ccc2cc(-c3ccccc3)c(C(=O)C(=O)Nc3ccc(C(C)=O)cc3)n2c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.45
THRB P10828 1/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 3/20 0.43
MAPT P10636 5/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 3/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 4/20 0.40
RAB9A P51151 3/20 0.40
CTDSP1 Q9GZU7 2/20 0.40
MEN1 O00255 2/20 0.40
CYP3A4 P08684 1/20 0.40
NPC1 O15118 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885596 0.94 CYP19A1 (0.47) CYP19A1THRBLMNASMN1; SMN2HTT
SCHEMBL1643301 0.93 POLB (0.49) CYP19A1THRBLMNASMN1; SMN2HTT
SCHEMBL1645639 0.90 SMN1; SMN2 (0.47) CYP19A1THRBLMNASMN1; SMN2HTT
SCHEMBL1645179 0.87 MAPT (0.46) THRBLMNASMN1; SMN2HTTMAPT
SCHEMBL1646571 0.83 LMNA (0.45) THRBLMNASMN1; SMN2HTTMAPT
SCHEMBL1644781 0.83 THRB (0.63) THRBLMNASMN1; SMN2HTTMAPT
SCHEMBL3884047 0.82 POLB (0.43) CYP19A1THRBLMNASMN1; SMN2HTT
SCHEMBL1644769 0.82 THRB (0.61) CYP19A1THRBLMNASMN1; SMN2HTT
SCHEMBL3888660 0.80 KDM4E (0.43) MAPTPOLBKMT2ARAB9ANPC1
SCHEMBL3890527 0.79 THRB (0.49) CYP19A1THRBLMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 CYP19A1 97/4885THRB 2955/4885LMNA 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.